Davide Capodanno/X
Jul 8, 2025, 07:56
AUREA – No Added Benefit of Short-Term OAC Post-TAVI in Patients Without OAC Indication
Davide Capodanno, Professor of Cardiology at University of Catania, Italy has posted on X:
“In the randomized, open-label AUREA trial, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism in patients without an indication for OAC. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol.”
You can read the Full Article here.
Explore more on Hemostasis Today.
-
Nov 6, 2025, 08:24Jacqui McCallum Reflects on Meeting with The Royal Melbourne Hospital Stroke and Neurology Ward Team
-
Nov 6, 2025, 08:17Maxime Dely: The True Heroes of Blood Donation Are Them!
-
Nov 6, 2025, 07:11Francesco Giurazza on Radial Access for Liver Transarterial Chemoembolization
-
Nov 6, 2025, 07:04Andrea Van Beek: Proud to be a Certified Anticoagulation Care Provider (CACP)!
-
Nov 6, 2025, 06:57Jian-Ke Tie’s Team on Comorbidity of VitK-dependent Clotting Factors Deficiency and Chondrodysplasia Punctata
-
Nov 6, 2025, 04:17Aakanksha A To Present Insights from ASH Education Social Media Initiative at 67th ASH Meeting
-
Nov 6, 2025, 04:03Yaping Zhang on Two-Way GPIb-IX Signaling in Platelet Activation and VWF Binding
-
Nov 6, 2025, 03:38Thierry Burnouf on Platelet-Derived Extracellular Vesicles and Their Role in Neurogenesis
-
Nov 6, 2025, 03:29Shubham Misra to Present 3 Abstracts at International Stroke Conference 2026
Nov 6, 2025, 08:17
Nov 5, 2025, 10:45
Nov 5, 2025, 10:43